Novo Nordisk has become the latest partner to join BaseLaunch.
Novo Nordisk joins other world-class pharma, venture fund and biotechnology partners – Roche, Johnson & Johnson, CSL Behring, Pureos Bioventures, CMS, Roivant Sciences and Bridge Biotherapeutics – in supporting BaseLaunch’s mission to build the next generation of innovative biotech companies. This will strengthen BaseLaunch’s global pharma industry ties and further enhance its ability to deliver tangible results for scientists and entrepreneurs developing innovative biotech companies.
To date, BaseLaunch has supported multiple successful early-stage biotech ventures from inception to Series A funding, providing financing and assisting in all aspects of company development. Of the 22 ventures supported by BaseLaunch since 2018, ten have so far collectively raised over USD 600 million in equity capital, with six ventures to date having entered clinical development. Boehringer Ingelheim’s recent USD 500 million acquisition of T3 Pharma, one of the first companies supported by BaseLaunch, exemplifies BaseLaunch’s standing as a world-leader in building biotech ventures and is a testament to the strength of the Basel region, arguably Europe’s most dynamic life sciences hub.
Read more here.
